French drugmaker Ipsen (Euronext: IPN) has bought an option on an oncology program from Montreal-based biotech group, IRICoR.
Based at the Institute for Research in Immunology and Cancer (IRIC), IRICoR is a pan-Canadian research commercialization center based at the Université de Montreal, Canada.
The option agreement gives Ipsen rights to acquire an exclusive global license for the program, which is currently at lead optimization stage.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze